Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gibbs

Showing results (211-220 of 427) with videos related to

Pageof 43
Sort By:
Internal Medicine Journal|March 1, 2019
Demonstrating the feasibility of collecting secondary, de-identified data on Australian patients receiving treatment as part of a Medicine Access ProgrammeSheau W Lok, Richard De Boer, Cassandra Cordwell, et al.
BMC Cancer|October 28, 2015
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinomaPeter Gibbs, Cuong Do, Lara Lipton, et al.
The Lancet Regional Health. Western Pacific|October 9, 2024
Population attributable fractions of depression and anxiety among Aboriginal and Torres Strait Islander peoples: a population-based studySubash Thapa, Kedir Y Ahmed, Santosh Giri, et al.
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
International Journal of Cancer|December 17, 2019
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancerJane Wolstenholme, Francesco Fusco, Alastair M Gray, et al.
Pharmacoeconomics|June 5, 2021
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal CancerYat Hang To, Koen Degeling, Suzanne Kosmider, et al.
Current Medical Imaging|June 2, 2026
Contralateral Breast Background Parenchymal Enhancement: A Physiologic Marker, not a Predictor of ER StatusDana Haddad, Stephanie B Shamir, Zoha Baig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapyRicky A Sharma, Guy A Van Hazel, Bruno Morgan, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
Cancer Research Communications|December 7, 2023
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT TrialJosep Tabernero, Takayuki Yoshino, Sebastian Stintzing, et al.
Pageof 43

Showing results (211-220 of 427) with videos related to

Sort By:
Pageof 43
Internal Medicine Journal|March 1, 2019
Demonstrating the feasibility of collecting secondary, de-identified data on Australian patients receiving treatment as part of a Medicine Access ProgrammeSheau W Lok, Richard De Boer, Cassandra Cordwell, et al.
BMC Cancer|October 28, 2015
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinomaPeter Gibbs, Cuong Do, Lara Lipton, et al.
The Lancet Regional Health. Western Pacific|October 9, 2024
Population attributable fractions of depression and anxiety among Aboriginal and Torres Strait Islander peoples: a population-based studySubash Thapa, Kedir Y Ahmed, Santosh Giri, et al.
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
International Journal of Cancer|December 17, 2019
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancerJane Wolstenholme, Francesco Fusco, Alastair M Gray, et al.
Pharmacoeconomics|June 5, 2021
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal CancerYat Hang To, Koen Degeling, Suzanne Kosmider, et al.
Current Medical Imaging|June 2, 2026
Contralateral Breast Background Parenchymal Enhancement: A Physiologic Marker, not a Predictor of ER StatusDana Haddad, Stephanie B Shamir, Zoha Baig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapyRicky A Sharma, Guy A Van Hazel, Bruno Morgan, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
Cancer Research Communications|December 7, 2023
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT TrialJosep Tabernero, Takayuki Yoshino, Sebastian Stintzing, et al.
Pageof 43